Abstract:No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic activities that may antagonize several pathophysiologic mechanisms induced by SARS-CoV-2, we hypothesize that this naturally occurring molecule is a promising agent to ameliorate COVID-19. We posit at least seven different mechanisms by which AAT may alleviate COVID-19. First, AAT is a serine protease inhibitor (SERPIN) shown to inhibit TMPRSS-2, the host serine protease that cleaves the spike protein of SARS-CoV-2, a necessary preparatory step for the virus to bind its cell surface receptor ACE2 to gain intracellular entry. Second, AAT has anti-viral activity against other RNA viruses HIV and influenza as well as induces autophagy, a known host effector mechanism against MERS-CoV, a related coronavirus that causes the Middle East Respiratory Syndrome. Third, AAT has potent anti-inflammatory properties, in part through inhibiting both nuclear factor-kappa B (NFκB) activation and ADAM17 (also known as tumor necrosis factor-alpha converting enzyme), and thus may dampen the hyper-inflammatory response of COVID-19. Fourth, AAT inhibits neutrophil elastase, a serine protease that helps recruit potentially injurious neutrophils and implicated in acute lung injury. AAT inhibition of ADAM17 also prevents shedding of ACE2 and hence may preserve ACE2 inhibition of bradykinin, reducing the ability of bradykinin to cause a capillary leak in COVID-19. Fifth, AAT inhibits thrombin, and venous thromboembolism and in situ microthrombi and macrothrombi are increasingly implicated in COVID-19. Sixth, AAT inhibition of elastase can antagonize the formation of neutrophil extracellular traps (NETs), a complex extracellular structure comprised of neutrophil-derived DNA, histones, and proteases, and implicated in the immunothrombosis of COVID-19; indeed, AAT has been shown to change the shape and adherence of non-COVID-19-related NETs. Seventh, AAT inhibition of endothelial cell apoptosis may limit the endothelial injury linked to severe COVID-19-associated acute lung injury, multi-organ dysfunction, and pre-eclampsia-like syndrome seen in gravid women. Furthermore, because both NETs formation and the presence of anti-phospholipid antibodies are increased in both COVID-19 and non-COVID pre-eclampsia, it suggests a similar vascular pathogenesis in both disorders. As a final point, AAT has an excellent safety profile when administered to patients with AAT deficiency and is dosed intravenously once weekly but also comes in an inhaled preparation. Thus, AAT is an appealing drug candidate to treat COVID-19 and should be studied.

Catalase‐Based Therapeutics: An Antioxidant Enzyme Therapeutic for COVID‐19 (Adv. Mater. 43/2020)

An Antioxidant Enzyme Therapeutic for COVID‐19

Exploring Therapeutic Potential of Catalase: Strategies in Disease Prevention and Management

Mitochondrial antioxidants abate SARS-COV-2 pathology in mice

An Antioxidant Enzyme Therapeutic for Sepsis

N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2

Cathepsins and SARS‐CoV‐2 infection: from pathogenic factors to potential therapeutic targets

Renalase Challenges the Oxidative Stress and Fibroproliferative Response in COVID-19

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Promising Enzymes for Inhibitors Development Against COVID-19

Reactive Sulfur Compounds in the Fight against COVID-19

Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19

Nanozymes for Antioxidant Therapy

N-Acetylcysteine to Combat COVID-19: An Evidence Review

High Expression of Recombinant Human Catalase and Its Immunomodulatory Effects on H1N1 Influenza Virus Infection

Enzymes in the time of COVID‐19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs

Integrating Pt Nanoparticles with Carbon Nanodots to Achieve Robust Cascade Superoxide Dismutase-Catalase Nanozyme for Antioxidant Therapy

Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection

On the dual role of (+)-catechin as primary antioxidant and inhibitor of viral proteases

Multiple Mechanisms of Action of Sulfodyne®, a Natural Antioxidant, against Pathogenic Effects of SARS-CoV-2 Infection

Therapeutic effects of high-dose vitamin C supplementation in patients with COVID-19: a meta-analysis